1
Clinical Trials associated with WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
The purpose of this study is to see if the investigator can help the immune system to work against myeloma.
This study will see if a vaccine made with altered dendritic cells will make T cells work against tumor cells. The stem cells collected for the transplant will also be used to grow dendritic cells in the lab. The dendritic cells will carry the antigens. These cells then will be injected under the skin. The investigators will do lab studies before and after the vaccination to find out if the vaccine is working.
100 Clinical Results associated with WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)
100 Translational Medicine associated with WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)
100 Patents (Medical) associated with WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)
100 Deals associated with WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)